UNSPSC 51413104: Razinodil

This classification denotes a vasodilating agent with the molecular formula C27H34N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJ1O5LVT0G, chemically known as 3,4,5-trimethoxybenzoic acid ester with 3-(2-hydroxy-3-morpholinopropyl)-6,7,8-trimethoxy-1,2,3-benzotriazin-4(3h)-one but generally known as razinodil, which bears US NIH Compound Identifier 65771. European Medicines Agency schedules Razinodil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10264MIG.

UNSPSC 51413104 Razinodil, a Commodity code, reflects state and local government procurement of emergency and critical-care medications supplied directly to emergency medical services and pharmacy benefit programs. Recent solicitations show purchasing departments and health agencies buying specific pharmaceutical products—Advanced Life Support medications including epinephrine, labetalol, adenosine, and diltiazem for emergency response; generic multi-source pharmaceuticals and over-the-counter products distributed through state and local health facilities; and direct-to-manufacturer prescription programs designed to improve fulfillment efficiency and cost control. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue through the City of Tampa's Purchasing Department), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). Procurement notice types range from sealed competitive bids to formal RFPs and exploratory RFIs, reflecting the mix of routine medication replenishment and strategic program redesign initiatives.

Activity under the code concentrates in the South and upper Midwest. The City of Tampa issued Bid No. 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with contract effectiveness July 1, 2026 and serving participating state and local facilities across Minnesota and Oregon. The Texas HHS Commission issued an exploratory RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling potential future formal procurement. Vendors should expect detailed product specifications, compliance with FDA and Drug Supply Chain Security Act requirements, established relationships with authorized wholesalers, and comprehensive insurance coverage including commercial general liability of $2 million to $5 million.